ArticleJournal of diabetes investigation2025
Genetic analysis of the correlation between GLP1 action and metabolic liver disease: Insights from Mendelian randomization analysis.
Article in Journal of diabetes investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposePrevious studies have shown that glucagon-like peptide 1 (GLP1) receptor agonists may help improve metabolic dysfunction-associated steatotic liver disease (MASLD), but supportive genetic data remain limited. Our study aims to explore the correlation between GLP1 action and MASLD.
methodsMendelian randomization (MR) was performed, with 22 cis-eQTLs and 2 missense mutations used as proxies for GLP1 action. MASLD data from the FinnGen study served as the primary analysis, with replication in an independent cohort. Subsequently, mediation analyses were conducted to explore the role of MASLD risk factors in the correlation between GLP1 action and MASLD. Finally, phenome-wide association studies (Phe-WAS) were performed.
resultsUsing cis-eQTLs as exposure, genetically predicted GLP1 action was associated with a decreased risk of MASLD in the primary analysis [IVW: odds ratio (OR): 0.36; 95% confidence interval (CI): 0.30-0.44; P = 1.37E-22] and in the replication study (IVW: OR: 0.61; 95% CI: 0.47-0.81; P = 5.58E-04). In mediation analyses, the proportion of the mediation effect of GLP1 action via type 2 diabetes was 6% (95% CI: 0.0004-0.1138; P = 4.70E-02), via hypertension was 4% (95% CI: 0.0128-0.0675; P = 3.82E-03), while via high-density lipoprotein cholesterol was 1% (95% CI: 0.0039-0.0187; P = 2.52E-03). Using missense mutations as exposure, no causal relationship between GLP1 action and MASLD was observed. Phe-WAS showed cardiovascular and renal benefits of GLP1 action.
conclusionsOur genetic analysis suggests a possible causal relationship between GLP1 action and MASLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.